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Background: Severe congenital neutropenia (SCN) is an immunodeficiency disease characterized low blood
neutrophil counts, early bacterial infections, and risk of leukaemia development. Heterozygous mutations in the
ELANE gene coding neutrophil elastase are associated with SCN. Patients with SCN suffer from recurrent bacterial
infections and often succumb them. To our knowledge, this is the first report of SCN from Vietnam.
Case presentation: A 6-year-old boy was admitted due to severe bacterial infection and severe neutropenia. He
had recurrent infections from 8 months of age, and was misdiagnosed with tuberculosis and and autoimmune
neutropenia in infancy at 21 and 41 months of age, respectively. His medical report has showed severe neutropenia
for many times. In direct DNA sequencing analysis, we found an ELANE gene mutation (R81P), which had been
confirmed to cause SCN.
Conclusion: The missed and delayed diagnosis may be attributable to insufficient awareness of this rare disease
on the background of frequent infections even in the immunocompetent pediatric population in Vietnam. Our
results indicate further evidence for the role of ELANE in SCN.
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Severe chronic neutropenia is a heterogeneous group of
rare disorders due to intrinsic defect of myeloid cell
proliferation and maturation [1]. Typically, severe con-
genital neutropenia (SCN) is defined by extremely low
absolute neutrophil count (ANC) (<0.5 × 109/L for at
least three months) and recurrent life-threatening bac-
terial infections. The incidence of SCN is estimated
to be 1 in 200,000 individuals [2]. Among several as-
sociated genetic mutations, heterogeneous mutations
of the ELANE gene coding for neutrophil elastase (NE)
have been associated with both SCN and cyclic neutro-
penia (CN), and it is known to be correlated with more* Correspondence: vvquang@hpmu.edu.vn
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unless otherwise stated.severe neutropenia and serious clinical manifestation in
SCN [1,3,4].
There have few reports of SCN from developing coun-
tries. Moreover, clinical signs of this rare condition
are frequently overlapped with other infectious diseases,
sometimes resulting delayed or missed diagnosis. Herein,
we report for the first time a Vietnamese boy with SCN,
confirmed by mutation analysis of the ELANE gene in
an attempt to improve the diagnosis and management
of SCN.Case presentation
A 6-year-old boy was hospitalized at Haiphong Children
Hospital because of phlegmon behind his right ear and
high fiver (40°C). Physical examination exhibited con-
sciousness, pale skin, cutaneous abscess behind right
ear, pustulosis on skin, foot fungus, and mouth ulceris an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,












10 20,1 0,6 12,4 6,6
17 10,2 0,58 4,8 5,08
18 9,2 0,01 5,9 2,67
23a 13,2 3,43 6,6 3,17
41b 6,48 1,6 2,6 1,9
41c 7,09 0,21 2,26 3,55
42 7,98 0,95 3,19 3,43
43 7,7 0,6 4,46 2,77
45 6,79 0,33 3,87 2,77
48 9,54 1,33 7,5 0,57
48 8,8 5,34 3,69 0,9
49 9,34 0,09 7,65 1,12
57 6,64 0,03 2,98 3,09
58 5,18 0,28 3,26 1,21
70 6,76 0,02 2,88 2,94
WBC, white blood cell count; ANC, absolute neutrophil count; a, starting
antituberculosis drugs; b, before giving solumedrol; c, after giving solumedrol.
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neutropenia (white blood cells, 6.9 × 109/L; neutro-
phils, 0.2 × 109/L; lymphocytes, 2.67 × 109/L; monocytes,
3.38 × 109/L). A gram-stain and culture of abscess fluid
showed S. aureus, which was susceptible to vacomycin
and amikacin. Bone marrow aspirate exhibited normal
myeloid cells, reduced granulocyte cell line, but no malig-
nant cells. Serum titers of IgG, IgM, IgA and IgE and per-
centage of CD4+, CD8+ T cells were normal. Tests of
HIV, HBV, HCV, EBV, and CMV were negative. The pa-
tient was treated with antibiotics according to antimicro-
bial susceptibility testing, abscess incision and drainage,
and G-CSF. Two weeks later, the patient was discharged
from hospital.
Because of severe neutropenia and infection, we carefully
asked medical history and analysed medical records of the
patient. From 8 months of age, the patient had recurrent
infections, Staphylococcal pneumonia and Staphylococcal
septicemia at 10 and 15 moths of age, respectively. In
addition, he had cutaneous abscesses and other respiratory
infections frequently. Because his infection status was not
fully recovered by using antibiotics, from 23 to 30 months
of age, the patient was treated with antituberculosis drugs
although there was not any evidence of mycobacterium tu-
berculosis. At the 41 months of age, the patient had necro-
tizing pneumonia due to S. aureus leading right parietal
lobectomy (Figure 1B). At that time, he was diagnosed with
autoimmune neutropenia in infancy (AIN) although anti-
neutrophil antibodies were not performed. After using
solumedrol, neutropenia and infection statuses got worse.
Moreover, patient had severe neutropenia in many times
(Table 1).
Considering his medical history, current clinical signs,
and laboratory findings, SCN associated with ELANEFigure 1 A number of lesions caused by infection. (A) cutaneous
abscess behind the right ear; (B) right parietal lobectomy; (C) fungal
infection; (D) mouth ulcer.abnormality was suspected. Direct DNA sequencing ana-
lysis demonstrated a heterozygous missense mutation of
the 242th base (G to C) in exon 3, resulting change of
the 81 codon (Arginine to Proline), which has been re-
ported to cause severe neutropenia (R81P) (Figure 2).
Conclusions
SCN is a very rare condition that is diagnosed when
ANC is less than 0.5 × 109/L for at least three months.
Patients with SCN exhibited recurrent life-threatening
infections, and a maturation arrest of bone marrow mye-
loid precursors at the promyelocyte-myelocyte stage of
differentiation [4,5]. The boy we herein report showed
typical manifestations of SCN including severe neutro-
penia and recurrent bacterial infections. However, the
diagnosis was missed and delayed until six years of age.
This issue can be explained by some reasons: Vietnam is
a tropical country where infectious diseases are very
popular and there is an insufficient awareness of this
rare disease on the background of frequent infections even
in immunocompetent pediatric population [6]. Moreover,
some infections can cause neutropenia such as tubercu-
losis, Dengue, measles, EV71, HIV, EBV, CMV… There-
fore, neutropenia in children really is a clinical challenge
for Vietnamese pediatricians especially during the first visit.
Because of high prevalence of tuberculosis in Vietnam [7]
and non-recovery by routine antibiotics, tuberculosis was
suspected in our patient, reflecting an impasse in treat-
ment of infectious diseases without adequate attention
Figure 2 Sequencing the genomic PCR products, heterozygous
missense mutation (R81P)(G changing to C) was identified.
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autoimmune neutropenia (AIN) requires more time for
observing the clinical course, but it is important due to
specific treatment [8-10]. We were confused because
absolute neutrophil count of the patient was sometime
elevated. Moreover, AIN is the most common type of
chronic neutropenia, the patient was suspected to AIN.
However, the more solumedrol he received, the more his
neutrophil counts reduced. After treatment with solume-
drol, the patient was overwhelming infections, and his
ANC was extremely decreased (Table 1). To confirm AIN,
detecting anti-neutrophil antibodies is very important but
not available in Vietnam now. Carefully analyzing clinical
courses of chronic neutropenia patients could contribute
to critical clues for different diagnosis. In contract to SCN
patients, AIN patients often have mild phenotypes with
minor intercurrent infections despite severe neutropenia;
their neutrophil counts could vary considerably from day
to day and often rise during acute infection without cor-
ticosteroid, epinephrine, or G-CSF treatment. Since it is
difficult to diagnosis AIN based only on peripheral neutro-
phil counts and past history, a bone marrow aspiration
test is necessary for differential diagnosis [8,10]. Because
the patient had severe phenotypes with life-threatening in-
fections, chronic severe neutropenia, and reduced gran-
ulocyte cell line on bone marrow aspirate, we suspected
SCN. After receiving G-CSF (6 mg/kg/24 h) his neutrophil
counts were increased dramatically, excluding mutations
of the patient’s G-CSF receptor gene.To confirm SCN diagnosis, we analyzed the ELANE
gene mutation firstly because it is the most common
gene alteration in SCN (about 50% of SCN and nearly all
of CN) [1,5,11]. There have been about 100 reported
ELANE variants in SCN and CN worldwide. In exon3, we
found a heterozygous missense mutation (R81P) (Figure 2).
This mutation has been reported to cause severe congeni-
tal neutropenia. Because ELANE gene has a leader se-
quence of 29 amino acids, the codon number of the
mutation may be also shown as “R52P” [1]. SCN due to
ELANE mutations causes persistent neutropenia, but sur-
prisingly, ANC of the patient was occasionally elevated. It
is difficult to explain, but exceptions may be attributable to
infection at the time of blood sampling, which may transi-
ently increase neutrophil production in the patient. More-
over, the disease phenotype is not determined by mutation
alone; it can be influenced by genetic, epigenetic, environ-
mental factors in specific time [6,12,13]. To date, this is the
first SCN case confirmed by genetic analysis in Vietnam.
As the estimated incidence of SCN is 1/200 000 [2], it is
suggested that many SCN cases in Vietnam may be un-
diagnosed. Because G-CSF therapy is available and stem
cell transplantation from HLA-identical sibling is the opti-
mal therapeutic modality, early diagnosis is of great im-
portance. National networks and diagnostic guideline for
SCN may be helpful for us to improve these issues. Be-
cause our patient has an older sibling, we closely follow
him with the idea of stem cell transplantation.
In summary, we describe a Vietnamese boy with typ-
ical phenotype of SCN but missed and delayed diagnosis.
This is the first report of SCN definitively diagnosed by
genetic analysis from Vietnam. The missed and delayed
diagnosis may be attributable to insufficient awareness
of this rare disease on the background of frequent infec-
tions even in the immunocompetent pediatric popula-
tion in Vietnam.
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